Is this your company? Get featured or correct your listing →
Recent changes
- Oct 19, 2026Oct 19, 2026Metis TechBio Inks Up To $1.1B Drug-Delivery Deal With Eli Lilly Pulse story
- Sep 24, 2026Sep 24, 2026Eli Lilly Wants In On Oura's IPO, Filings Show Profit Pulse story
- Jun 30, 2026Jun 30, 2026Invested in Flare Therapeutics (Series C, $85M) GlobeNewswire
Latest Pulse
- Oct 19, 2026Metis TechBio Inks Up To $1.1B Drug-Delivery Deal With Eli LillyHong Kong-listed Metis TechBio struck a collaboration with Eli Lilly worth up to $1.1 billion in milestone payments, using its AI-driven lipid nanoparticle platform to help Lilly's drugs reach specific tissues more precisely.→
- Oct 13, 2026TRexBio Closes $116.7M IPO, Lilly Eyes Bigger StakeTRexBio closed its IPO on Oct. 13, selling 8.33 million shares at $14 for about $116.7 million, with largest shareholder Eli Lilly signaling interest in raising its stake.→
- Oct 13, 2026Retension's $45M IPO Window Closes On ScheduleRetension Pharmaceuticals' upsized $45 million IPO was expected to close on or about Oct. 13, days after the hypertension-drug developer's shares began trading on Nasdaq.→
- Oct 12, 2026Forbion Closes Record $2.6B Across Two FundsLife sciences investor Forbion closed €2.3 billion ($2.6 billion) across two new funds, its largest fundraise in 20 years, lifting total assets under management to about €7.5 billion.→
- Sep 27, 2026Is Oura Really The Fall's Healthiest IPO?Oura prices its Nasdaq debut this week at a targeted $15.6B valuation on real GAAP profit and 74% revenue growth -- unusually strong for hardware -- but a $924M reported net loss from a stock buyback accounting quirk complicates the pitch.→
- Sep 24, 2026This Fall's IPO Cohort, Scored Deal By DealSix live IPO storylines this week produced wildly different outcomes -- from a 19% Hong Kong pop to a pulled US deal -- and the spread says this fall's IPO window rewards individual fundamentals, not just good timing.→
- Sep 24, 2026Eli Lilly Wants In On Oura's IPO, Filings Show ProfitEli Lilly indicated interest in buying up to $100 million of Oura's IPO shares, and updated filings show the smart-ring maker is actually profitable, with $60.8 million in net income over nine months.→
- Sep 21, 2026TRex Bio, Retension File S-1s For Nasdaq IPOsTRex Bio and Retension Pharmaceuticals both filed S-1 registration statements for Nasdaq IPOs on the same day, joining a fall biotech listing wave with Eli Lilly backing TRex's autoimmune-disease pipeline.→
- Sep 15, 2026Thatch Hits Unicorn Status As Health Costs SurgeThatch, an ICHRA marketplace that lets employers fund individual health plans instead of one group policy, raised a $108 million Series C at a $1 billion valuation as revenue grew nearly sevenfold over the past year.→
- Sep 8, 2026Moonwalk Biosciences Raises $70M For Obesity RNAiMoonwalk Biosciences closed an oversubscribed $70 million Series B to advance an adipose-targeted RNA interference therapy for obesity toward its first human trial, bringing total funding to roughly $127 million since its 2024 launch.→
Coverage Timeline
newest first- Oct 19, 2026AIMetis TechBio Inks Up To $1.1B Drug-Delivery Deal With Eli LillyUp To $1.1B Deal→
- Oct 13, 2026IPOTRexBio Closes $116.7M IPO, Lilly Eyes Bigger Stake$116.7M IPO→
- Sep 24, 2026IPOEli Lilly Wants In On Oura's IPO, Filings Show Profit→
- Jul 10, 2026IPODoudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO$180M+ partnership payments→
All Coverage
AIUp To $1.1B Deal
Metis TechBio Inks Up To $1.1B Drug-Delivery Deal With Eli Lilly
Hong Kong-listed Metis TechBio struck a collaboration with Eli Lilly worth up to $1.1 billion in milestone payments, using its AI-driven lipid nanoparticle platform to help Lilly's drugs reach specific tissues more precisely.
DEEP DIVE
TRexBio Closes $116.7M IPO, Lilly Eyes Bigger Stake
IPO$116.7M IPO
TRexBio Closes $116.7M IPO, Lilly Eyes Bigger Stake
TRexBio closed its IPO on Oct. 13, selling 8.33 million shares at $14 for about $116.7 million, with largest shareholder Eli Lilly signaling interest in raising its stake.
DEEP DIVE
Eli Lilly Wants In On Oura's IPO, Filings Show Profit
IPO
Eli Lilly Wants In On Oura's IPO, Filings Show Profit
Eli Lilly indicated interest in buying up to $100 million of Oura's IPO shares, and updated filings show the smart-ring maker is actually profitable, with $60.8 million in net income over nine months.
FOLLOW-UP
Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO
IPO$180M+ partnership payments
Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO
Scribe Therapeutics, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, amended its S-1 to list on Nasdaq under ticker SCTX, backed by more than $180 million in Sanofi and Eli Lilly partnership payments.
Value Add Research
- VC & Investing · Oct 20, 2026Lycia Therapeutics IPO 2026: $938M Valuation, LYCA Ticker
- Fundraising · Oct 14, 2026TRexBio IPO 2026: $116.7M Raise, Lilly Eyes Bigger Stake
- VC & Investing · Sep 30, 2026ADARx IPO: $1.81B Valuation, $446M Raised (ADRX)
- Startup Operations · Sep 17, 2026Thatch Valuation: $1B After $108M Series C in 2026
- VC & Investing · Sep 7, 2026Menlo Ventures 2026: $3B Fund, $14B Anthropic Stake, New Deals
- VC & Investing · Jul 15, 2026$400M at $3.8B — Chai Discovery AI Drug Design
- Market & Trends · Jul 10, 2026$5B+ Raised — AI Drug Discovery Startups (2026)
- Market & Trends · Jun 14, 2026GLP-1 Drug Startups 2026: $157B Market and $471M VC Funding
Related Companies
Eli Lilly FAQ
Is Eli Lilly publicly traded?
Yes. Eli Lilly trades.